Bart Kesteleyn, Jean-François Bonfanti, Dorothée Bardiot, Benoît De Boeck, Olivia Goethals, Suzanne J F Kaptein, Bart Stoops, Erwin Coesemans, Jérôme Fortin, Philippe Muller, Frédéric Doublet, Gunter Carlens, Mohamed Koukni, Wim Smets, Pierre Raboisson, Patrick Chaltin, Kenny Simmen, Marnix Van Loock, Johan Neyts, Arnaud Marchand, Tim H M Jonckers
Dengue is a global public health threat, with about half of the world's population at risk of contracting this mosquito-borne viral disease. Climate change, urbanization, and global travel accelerate the spread of dengue virus (DENV) to new areas, including southern parts of Europe and the US. Currently, no dengue-specific small-molecule antiviral for prophylaxis or treatment is available. Here, we report the discovery of JNJ-1802 as a potent, pan-serotype DENV inhibitor (EC50 's ranging from 0.057 to 11 nM against the four DENV serotypes)...
March 14, 2024: Journal of Medicinal Chemistry